Cover Image
市場調查報告書

卡那凡氏症:開發中產品分析

Canavan Disease - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361639
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
卡那凡氏症:開發中產品分析 Canavan Disease - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 44 Pages
簡介

本報告提供卡那凡氏症治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

卡那凡氏症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

卡那凡氏症:企業開發中的治療藥

卡那凡氏症:大學/機關研究中的治療藥

卡那凡氏症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

卡那凡氏症:企業開發中的產品

卡那凡氏症:大學/機關研究中的產品

卡那凡氏症的治療藥的開發企業

  • StemCells, Inc.
  • Turing Pharmaceuticals AG

卡那凡氏症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

卡那凡氏症:最近的開發平台趨勢

卡那凡氏症:暫停中的計劃

附錄

目錄
Product Code: GMDHC8155IDB

Summary

Global Markets Direct's, 'Canavan Disease - Pipeline Review, H1 2016', provides an overview of the Canavan Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Canavan Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Canavan Disease
  • The report reviews pipeline therapeutics for Canavan Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Canavan Disease therapeutics and enlists all their major and minor projects
  • The report assesses Canavan Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Canavan Disease

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Canavan Disease
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Canavan Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Canavan Disease Overview
  • Therapeutics Development
    • Pipeline Products for Canavan Disease - Overview
    • Pipeline Products for Canavan Disease - Comparative Analysis
  • Canavan Disease - Therapeutics under Development by Companies
  • Canavan Disease - Therapeutics under Investigation by Universities/Institutes
  • Canavan Disease - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Canavan Disease - Products under Development by Companies
  • Canavan Disease - Products under Investigation by Universities/Institutes
  • Canavan Disease - Companies Involved in Therapeutics Development
    • StemCells, Inc.
    • Turing Pharmaceuticals AG
  • Canavan Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Gene Therapy 2 to Activate Aspartoacylase for Canavan Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HuCNS-SC - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pegylated Aspartoacylase for Canavan Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy to Activate Aspartoacylase for Canavan Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TUR-007 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Canavan Disease - Recent Pipeline Updates
  • Canavan Disease - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Canavan Disease, H1 2016
  • Number of Products under Development for Canavan Disease - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Canavan Disease - Pipeline by StemCells, Inc., H1 2016
  • Canavan Disease - Pipeline by Turing Pharmaceuticals AG , H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Canavan Disease Therapeutics - Recent Pipeline Updates, H1 2016
  • Canavan Disease - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Canavan Disease, H1 2016
  • Number of Products under Development for Canavan Disease - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top